Display options
Cite
Taylor TG, Venable PW, Shibayama J, et al. Role of KATP channel in electrical depression and asystole during long-duration ventricular fibrillation in ex vivo canine heart. Am J Physiol Heart Circ Physiol. 2012;302(11):H2396-409doi: 10.1152/ajpheart.00752.2011.
Taylor, T. G., Venable, P. W., Shibayama, J., Warren, M., & Zaitsev, A. V. (2012). Role of KATP channel in electrical depression and asystole during long-duration ventricular fibrillation in ex vivo canine heart. American journal of physiology. Heart and circulatory physiology, 302(11), H2396-409. https://doi.org/10.1152/ajpheart.00752.2011
Taylor, Tyson G, et al. "Role of KATP channel in electrical depression and asystole during long-duration ventricular fibrillation in ex vivo canine heart." American journal of physiology. Heart and circulatory physiology vol. 302,11 (2012): H2396-409. doi: https://doi.org/10.1152/ajpheart.00752.2011
Taylor TG, Venable PW, Shibayama J, Warren M, Zaitsev AV. Role of KATP channel in electrical depression and asystole during long-duration ventricular fibrillation in ex vivo canine heart. Am J Physiol Heart Circ Physiol. 2012 Jun 01;302(11):H2396-409. doi: 10.1152/ajpheart.00752.2011. Epub 2012 Mar 30. PMID: 22467302; PMCID: PMC3378304.
Copy Download .nbib Format: NLM
Share it on

Am J Physiol Heart Circ Physiol. 2012 Jun 01;302(11):H2396-409. doi: 10.1152/ajpheart.00752.2011. Epub 2012 Mar 30.

Role of KATP channel in electrical depression and asystole during long-duration ventricular fibrillation in ex vivo canine heart.

American journal of physiology. Heart and circulatory physiology

Tyson G Taylor, Paul W Venable, Junko Shibayama, Mark Warren, Alexey V Zaitsev

Affiliations

  1. Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, 84112-5000, USA.

PMID: 22467302 PMCID: PMC3378304 DOI: 10.1152/ajpheart.00752.2011

Abstract

Long-duration ventricular fibrillation (LDVF) in the globally ischemic heart is characterized by transmurally heterogeneous decline in ventricular fibrillation rate (VFR), emergence of inexcitable regions, and eventual global asystole. Rapid loss of both local and global excitability is detrimental to successful defibrillation and resuscitation during cardiac arrest. We sought to assess the role of the ATP-sensitive potassium current (I(KATP)) in the timing and spatial pattern of electrical depression during LDVF in a structurally normal canine heart. We analyzed endo-, mid-, and epicardial unipolar electrograms and epicardial optical recordings in the left ventricle of isolated canine hearts during 10 min of LDVF in the absence (control) and presence of an I(KATP) blocker glybenclamide (60 μM). In all myocardial layers, average VFR was the same or higher in glybenclamide-treated than in control hearts. The difference increased with time of LDVF and was overall significant in all layers (P < 0.05). However, glybenclamide did not significantly affect the transmural VFR gradient. In epicardial optical recordings, glybenclamide shortened diastolic intervals, prolonged action potential duration, and decreased the percentage of inexcitable area (all differences P < 0.001). During 10 min of LDVF, asystole occurred in 55.6% of control and none of glybenclamide-treated hearts (P < 0.05). In three hearts paced after the onset of asystole, there was no response to LV epicardial or atrial pacing. In structurally normal canine hearts, I(KATP) opening during LDVF is a major factor in the onset of local and global inexcitability, whereas it has a limited role in overall deceleration of VFR and the transmural VFR gradient.

References

  1. Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1753-66 - PubMed
  2. J Mol Cell Cardiol. 2005 Jul;39(1):61-70 - PubMed
  3. Cardiovasc Res. 1996 Sep;32(3):593-603 - PubMed
  4. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1617-28 - PubMed
  5. Resuscitation. 2009 Jan;80(1):24-9 - PubMed
  6. Circulation. 1993 Dec;88(6):2903-15 - PubMed
  7. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2589-97 - PubMed
  8. Am J Physiol. 1995 Dec;269(6 Pt 2):H1998-2009 - PubMed
  9. Ann Biomed Eng. 2001 May;29(5):414-26 - PubMed
  10. Circ Res. 2004 Apr 2;94(6):836-42 - PubMed
  11. Resuscitation. 2003 Jul;58(1):31-5 - PubMed
  12. Am J Physiol. 1994 Apr;266(4 Pt 2):H1322-6 - PubMed
  13. Circ Res. 1991 Jun;68(6):1693-702 - PubMed
  14. J Mol Cell Cardiol. 1997 Feb;29(2):845-8 - PubMed
  15. Circ Res. 1990 Oct;67(4):835-43 - PubMed
  16. J Mol Cell Cardiol. 2011 Aug;51(2):215-25 - PubMed
  17. Circ Res. 1997 Jan;80(1):124-38 - PubMed
  18. Circ Res. 2011 Nov 11;109(11):1309-18 - PubMed
  19. J Am Coll Cardiol. 2002 Apr 17;39(8):1323-8 - PubMed
  20. N Engl J Med. 2007 Mar 15;356(11):1140-51 - PubMed
  21. Heart Rhythm. 2009 Mar;6(3):378-84 - PubMed
  22. J Pharmacol Exp Ther. 1992 Aug;262(2):809-17 - PubMed
  23. FEBS Lett. 1998 Nov 27;440(1-2):125-30 - PubMed
  24. Ann N Y Acad Sci. 1994 Jun 17;723:392-5 - PubMed
  25. Circ Res. 1991 Sep;69(3):623-37 - PubMed
  26. J Pharmacol Exp Ther. 2005 Jan;312(1):61-8 - PubMed
  27. Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H1984-91 - PubMed
  28. IEEE Trans Biomed Eng. 2002 Dec;49(12 Pt 2):1639-41 - PubMed
  29. J Gen Physiol. 1993 Apr;101(4):603-26 - PubMed
  30. Ann Emerg Med. 1984 Apr;13(4):237-43 - PubMed
  31. Am J Physiol Heart Circ Physiol. 2004 May;286(5):H2001-9 - PubMed
  32. Circulation. 2000 Oct 10;102(15):1780-7 - PubMed
  33. Resuscitation. 2007 Sep;74(3):418-26 - PubMed
  34. Br J Pharmacol. 1999 Nov;128(6):1175-80 - PubMed
  35. Resuscitation. 2008 Jan;76(1):31-6 - PubMed
  36. Resuscitation. 2009 Sep;80(9):975-6 - PubMed
  37. J Cardiovasc Pharmacol Ther. 1996 Oct;1(4):307-312 - PubMed
  38. Am J Cardiol. 1985 Mar 1;55(6):813-20 - PubMed
  39. Prog Cardiovasc Dis. 2008 Nov-Dec;51(3):213-28 - PubMed
  40. J Physiol. 2008 Jun 1;586(11):2767-78 - PubMed
  41. Cardiovasc Res. 2000 Nov;48(2):300-9 - PubMed
  42. JAMA. 2002 Dec 18;288(23):3008-13 - PubMed
  43. Circulation. 2007 Sep 4;116(10):1113-9 - PubMed
  44. J Cardiovasc Electrophysiol. 1998 Mar;9(3):292-8 - PubMed
  45. Am J Physiol. 1985 Aug;249(2 Pt 2):H241-8 - PubMed
  46. Prehosp Emerg Care. 2006 Jan-Mar;10(1):52-60 - PubMed
  47. Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H154-62 - PubMed
  48. Circ Res. 1993 May;72(5):973-83 - PubMed
  49. Heart Rhythm. 2009 Jun;6(6):796-802 - PubMed
  50. Am J Physiol. 1996 Jul;271(1 Pt 2):H140-7 - PubMed
  51. Circ Res. 1993 Mar;72(3):671-87 - PubMed
  52. Circulation. 1989 Dec;80(6):1675-80 - PubMed
  53. Circulation. 1989 Jul;80(1):165-77 - PubMed
  54. Br J Pharmacol. 1999 Aug;127(7):1687-95 - PubMed
  55. Am J Physiol Heart Circ Physiol. 2000 Oct;279(4):H1609-15 - PubMed
  56. J Pharmacol Exp Ther. 2001 Aug;298(2):598-606 - PubMed
  57. Science. 1990 Mar 16;247(4948):1341-4 - PubMed
  58. Circulation. 2006 Aug 8;114(6):536-42 - PubMed
  59. Europace. 2010 Feb;12(2):254-60 - PubMed
  60. J Clin Invest. 2005 Dec;115(12):3527-35 - PubMed
  61. Mol Cell Biochem. 2003 Jan;242(1-2):81-7 - PubMed
  62. Circ Res. 2003 Mar 21;92(5):546-53 - PubMed
  63. J Cardiovasc Electrophysiol. 2007 Dec;18(12):1306-12 - PubMed
  64. Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1405-18 - PubMed
  65. Circ Res. 1989 Oct;65(4):1157-60 - PubMed
  66. Circulation. 1993 Sep;88(3):1177-89 - PubMed
  67. Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H883-9 - PubMed

Substances

MeSH terms

Publication Types

Grant support